Novartis
Search results
As a pioneer in healthcare, we have been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.
Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.
About Roche. Throughout our 125-year history, Roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas.
F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel.
Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management.
Innovation across the Roche Group. Our close strategic partnerships across the Group, and our diverse mix of autonomous innovation engines gives us a rich diversity of expertise and scientific thinking, as we seek to discover and develop solutions to the biggest questions in healthcare today.
Roche Diagnostics develops innovative products and services that address the prevention, diagnosis, monitoring, screening and treatment of diseases.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.
Diagnostic solutions by types. At Roche Diagnostics, we develop diagnostic tests, instruments and digital solutions with the power to transform healthcare for people around the globe.
Four-plex test for SARS-CoV-2, Influenza A/B and RSV receives FDA Emergency Use Authorization. Now, HCPs will be able to detect and differentiate these respiratory viruses within a single patient visit, enabling improved public health outcomes.
